Bayforest Capital Ltd Buys 414 Shares of Natera, Inc. $NTRA

Bayforest Capital Ltd lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 15.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,057 shares of the medical research company’s stock after purchasing an additional 414 shares during the quarter. Bayforest Capital Ltd’s holdings in Natera were worth $516,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Natera by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company’s stock valued at $1,752,611,000 after purchasing an additional 77,357 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after acquiring an additional 660,538 shares during the last quarter. Invesco Ltd. grew its holdings in Natera by 13.7% during the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after acquiring an additional 245,719 shares during the last quarter. Finally, Maverick Capital Ltd. grew its holdings in Natera by 19.7% during the 1st quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company’s stock worth $231,173,000 after acquiring an additional 268,715 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of research reports. Cowen reissued a “buy” rating on shares of Natera in a report on Friday, August 8th. Canaccord Genuity Group reissued a “buy” rating and set a $200.00 target price on shares of Natera in a report on Tuesday. Wells Fargo & Company initiated coverage on shares of Natera in a report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 target price on the stock. Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 target price on the stock in a report on Monday, July 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $194.06.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $132.89, for a total transaction of $398,670.00. Following the transaction, the insider directly owned 123,059 shares of the company’s stock, valued at $16,353,310.51. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 14,083 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the transaction, the chief executive officer directly owned 154,072 shares in the company, valued at approximately $24,651,520. This represents a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,464 shares of company stock valued at $10,963,125 in the last ninety days. Insiders own 5.63% of the company’s stock.

Natera Stock Performance

NASDAQ:NTRA opened at $172.81 on Wednesday. The firm’s fifty day moving average is $165.98 and its 200-day moving average is $157.65. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00. The firm has a market cap of $23.72 billion, a P/E ratio of -90.48 and a beta of 1.74.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.